STOCK TITAN
  1. Home
  2. Sec-filings
  3. APVO
  4. [EFFECT] Aptevo Therapeutics Inc. SEC Filing

[EFFECT] Aptevo Therapeutics Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 30, 2026 4:30 P.M.
Form: S-1
CIK: 0001671584
Company Name: Aptevo Therapeutics Inc.
File Number: 333-293010

Source: View Original Filing on SEC EDGAR

Stock APVO logo
Aptevo Therapeutics Inc

NASDAQ:APVO

APVO Rankings

#6283 Ranked by Market Cap
N/A Ranked by Dividends
#59 Top Loser

APVO Latest News

Feb 3, 2026
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Jan 9, 2026
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Dec 26, 2025
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
Dec 9, 2025
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Nov 10, 2025
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

APVO Latest SEC Filings

Feb 3, 2026
[8-K] Aptevo Therapeutics Inc. Reports Material Event
Jan 30, 2026
[424B4] Aptevo Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(4)
Jan 28, 2026
[S-1] Aptevo Therapeutics Inc. Files IPO Registration Statement
Jan 26, 2026
[DEF 14A] Aptevo Therapeutics Inc. Definitive Proxy Statement
Jan 16, 2026
[PRE 14A] Aptevo Therapeutics Inc. Preliminary Proxy Statement

APVO Stock Data

11.35M
997.07k
0%
0.48%
3.11%
Biotechnology
Pharmaceutical Preparations
Link
United States
SEATTLE